CMS grants Medicare add-on payment status to Omeros's TA-TMA drug

Omeros Corporation (Nasdaq: OMER) announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status to YARTEMLEA (narsoplimab-wuug) under the Fiscal Year 2027 Hospital Inpatient Prospective Payment System Final Rule.

Beginning October 1, 2026, eligible hospitals treating Medicare patients with YARTEMLEA for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) will receive up to $287,079 in additional Medicare reimbursement per eligible inpatient. The payments go to hospitals and do not affect the amount Omeros receives for the drug.

YARTEMLEA is FDA-approved for the treatment of TA-TMA in adults and children two years of age and older. Omeros claims it is the first and only approved treatment for the condition, which the company describes as a rare complication of hematopoietic stem cell transplantation. Approximately 30% of patients undergoing allogeneic stem cell transplants in the United States are Medicare beneficiaries.

The NTAP program provides supplemental reimbursement to hospitals for new technologies before their costs are fully reflected in standard payment rates.

"CMS's decision is an important step in further facilitating hospital adoption of YARTEMLEA for Medicare patients," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "This additional reimbursement should help ensure that treatment decisions for Medicare patients are guided by clinical need rather than constrained by reimbursement considerations."

According to the press release, serious and life-threatening infections were reported in 36% of clinical trial patients treated with YARTEMLEA. The most common adverse reactions, occurring in 20% or more of patients, included viral infections, sepsis, hemorrhage, diarrhea, vomiting, nausea, neutropenia, pyrexia, fatigue, and hypokalemia.

You May Also Be Interested In

• RBC Capital Downgrades Spire Healthcare (SPI:LN) (SRRHF) to Sector Perform
• UBS Upgrades Arbonia AG (ARBN:SW) to Buy
• Computacenter Plc. (CCC:LN) PT Raised to GBP60 at JPMorgan